611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Basic InformationLatest News
Why Is Liver Cancer More Lethal for Black Patients?Pandemic Putting Added Strain on Parents of Kids With CancerMany Cancer Patients Worry Pandemic Will Impact Their Care: SurveyChronic Heartburn Raises Odds for Cancers of Larynx, EsophagusDrug Improves Survival for Rare, Deadly Kidney CancerInsight Into Why a Prostate Cancer Therapy Works Better for Black MenKnow the Signs of Rare But Deadly Gall Bladder, Bile Duct CancersAbnormal Stool Test Result? Don't Delay Your ColonoscopyEven Low-Intensity Exercise Can Help During Cancer TreatmentsCould Too Much Light at Night Raise Your Odds for Thyroid Cancer?After Long Decline, Breast Cancers in Young U.S. Women Are On the RiseDrug Combo May Boost Survival for Tough-to-Treat Liver CancersCancer Plagues California Sea Lions, With Implications for HumansWhen Heart Attack Strikes, Cancer Patients Often Miss Out on Lifesaving TreatmentBreast Cancer Surpasses Lung Cancer as Leading Cancer Diagnosis WorldwideSegregation, Poverty Tied to Worse Outcomes for Black Lung Cancer PatientsCould Working Outside Help Prevent Breast Cancer?Type 2 Diabetes Drug Metformin Could Help Prevent Some Breast CancersPandemic Has Greatly Slowed Pace of Cancer ResearchDiscovery Could Explain Why Black Americans More Prone to Colon CancerMale Breast Cancer Patients Face Higher Heart RisksTherapeutic Vaccine Is Keeping Melanoma in Remission 4 Years OnDaily Aspirin Can Lower Colon Cancer Risk, But Age MattersHow Smoking Could Help Spur Breast Cancer's SpreadEven When Cancer Is in Remission, Patients' Risks of Severe COVID RiseAlcohol Plays Role in U.S. Cancer Cases, Deaths: ReportFewer U.S. Cancer Patients Are Dying From Suicide, Study FindsProgram Helps Low-Income Women Get Needed MammogramsCancer Screening Fell Sharply Early in Pandemic, But Has ReboundedMore Breast Cancer Survivors Opting to 'Go Flat' After MastectomyU.S. Cancer Death Rates Keep Falling: ReportStudy Outlines Role of Oral Sex in Rare Throat, Mouth CancersToxin in Undercooked Meat Shows Links to Rare Brain TumorsFor Many Cancer Patients, Diagnosis Brings Psychological 'Silver Lining'Mediterranean Diet Could Help Stop Prostate Cancer's SpreadGenes Help Explain Role of Race in Prostate Cancer RiskNew Clues to How Cancers Originate in the BrainSurgery Could Boost Survival for Women With Advanced Breast Cancers: StudyCancer Survivors at Higher Odds for Second Cancer: StudyEven Winter Carries Skin Cancer Risks for College StudentsEsophageal Cancer on the Rise Among the Young: StudyObesity's Influence on Colon Cancer Risk May Vary by Gender: StudyPandemic Closures, Fears Keep Patients From Lung Cancer ScreeningCertain Cancer Patients at Higher Odds for Severe COVID-19Kids With Cancer Not at Greater Risk for Severe COVIDFans Could Help Cancer Patients Breathe Easier: StudyFor Cancer Patients, Holiday Season Can Be a Stressful TimeWhy Do Black Patients Fare Worse With Blood Cancer Than Whites?Mindfulness Helps Young Women After Breast Cancer: StudyMany Breast Cancer Survivors Have Healthy Babies: Study
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Drug Improves Survival for Rare, Deadly Kidney Cancer

HealthDay News
by Robert Preidt
Updated: Feb 22nd 2021

new article illustration

MONDAY, Feb. 22, 2021 (HealthDay News) -- The drug cabozantinib is more effective than two similar drugs, as well as the current standard treatment, in extending the lives of patients with a rare and deadly type of kidney cancer, according to a new study.

The cancer is called metastatic papillary kidney cancer. There are currently no effective treatments for it. A previous study of 38 patients found that the average survival rate was just eight months after diagnosis.

These findings could change how the cancer is treated, the research suggested.

"We still have a long way to go to help make patients' lives longer and better, but we do have a new standard treatment for these rare cancer patients," said study author Dr. Sumanta Pal, a clinical professor of medical oncology at City of Hope Cancer Center in Duarte, Calif. He's also a researcher in the SWOG Cancer Research Network.

Mutations in the MET gene are a hallmark of this type of this kidney cancer, and new drugs target the MET gene, along with other important signaling pathways.

In this study of 147 patients, researchers compared three MET target drugs -- cabozantinib, crizotinib and savolitinib -- with the current standard treatment, sunitinib, a receptor tyrosine inhibitor.

The patients, most of whom hadn't received any prior treatment, were randomly assigned to receive one of the four treatments.

Progression-free survival (the time it took before the cancer returned or spread) was a median of 5.6 months in the sunitinib group, and much shorter in the savolitinib and crizotinib groups.

However, it was 9.2 months in the cabozantinib group, and 23% of those patients had a significant reduction in the size of their tumor, versus 4% of those in the sunitinib group, the SWOG Cancer Research Network study found.

"The magnitude of the response was surprising," Pal added in a SWOG/City of Hope news release.

The study was presented earlier this month at a virtual American Society of Clinical Oncology meeting and published simultaneously in The Lancet journal.

SWOG Cancer Research Network is part of the U.S. National Cancer Institute's National Clinical Trials Network. City of Hope is an NCI-designated comprehensive cancer care center.

More information

The U.S. National Cancer Institute has more on papillary kidney cancer.

SOURCE: SWOG Cancer Research Network, City of Hope news release, Feb. 13, 2021